ClinicalTrials.gg
RecruitingNCT07560566Updated May 1, 2026

SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin

A Phase 2 interventional study of Topical Indomethacin in Hepato Cellular Carcinoma (HCC) and Hand Foot Skin Syndrome, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by National Taiwan University Hospital · Phase 2, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2025, registered Apr 2026).
  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Carcinoma, Hepatocellular by National Taiwan University Hospital — 8 open to participants now, 8 under way, none of them phase 3. Carcinoma, Hepatocellular · National Taiwan University Hospital.

Planned enrollment
11th of 25
39 · median 30
Started
2025
with 3 others
Phase 2
9 of 44
2 open now
Registered
43rd of 44
by date

Among the 44 studies in Carcinoma, Hepatocellular by National Taiwan University Hospital, this one is the 11th largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2025, is one of 9 in phase 2, and was the 43rd registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

8 of the 44 studies in Carcinoma, Hepatocellular by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Carcinoma, Hepatocellular by National Taiwan University Hospital, or all of them as a file.
02

Study summary

SHIELD is a single-center, open-label, single-arm prospective study designed to evaluate whether pre-emptive topical indomethacin can reduce sorafenib-associated hand-foot syndrome (HFS) in patients with advanced hepatocellular carcinoma (HCC). Eligible adult patients with advanced HCC who are planned to initiate sorafenib will receive standard sorafenib treatment together with prophylactic 1% topical indomethacin gel applied to both hands twice daily for up to 12 weeks, or until development of HFS or discontinuation of sorafenib, whichever occurs first. The primary endpoint is the incidence of all-grade HFS during the first 12 weeks of sorafenib treatment. Secondary endpoints include grade 2 or higher HFS rate, grade 3 or higher HFS rate, mean sorafenib dose intensity during the first 12 weeks, adverse events of special interest, and duration of sorafenib treatment. The study will enroll 39 patients and compare outcomes with historical control data.

Read the detailed description

This is a single-center, open-label, single-arm prospective study evaluating the prophylactic use of topical indomethacin for prevention of sorafenib-associated hand-foot syndrome (HFS) in patients with advanced hepatocellular carcinoma (HCC). Sorafenib is an established systemic treatment option for advanced HCC, but HFS is a frequent toxicity that may reduce quality of life and interfere with treatment delivery. Historical studies have reported all-grade HFS rates of approximately 45% in patients treated with sorafenib.

Topical NSAIDs have shown preventive activity against chemotherapy-related HFS in prior studies. Based on this rationale, this study will investigate whether pre-emptive administration of 1% topical indomethacin gel can reduce the incidence of sorafenib-related HFS while avoiding the systemic adverse effects associated with oral NSAIDs.

Eligible adult patients with advanced HCC who are planned to start sorafenib will receive sorafenib at an initial dose of 400 mg orally twice daily, with subsequent dose modification according to routine clinical practice. Participants will also apply 1% topical indomethacin gel to the palmar and dorsal surfaces of both hands twice daily (total 4 g/day) for up to 12 weeks, or until development of HFS or discontinuation of sorafenib, whichever occurs first.

The primary endpoint is the incidence of all-grade HFS during the first 12 weeks of sorafenib treatment, defined according to NCI CTCAE version 5.0. Secondary endpoints include the incidence of grade 2 or higher HFS, incidence of grade 3 or higher HFS, mean sorafenib dose intensity during the first 12 weeks, adverse events of special interest, and sorafenib treatment duration. A total of 39 patients will be enrolled. Outcomes will be interpreted against historical control data.

03

Conditions studied

  • Hepato Cellular Carcinoma (HCC)
  • Hand Foot Skin Syndrome

Keywords

  • hepatocellular carcinoma
  • Hand foot skin syndrome
  • Topical NSAID
  • Prophylaxis
  • Sorafenib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female or male patients, 18 years of age or older, able to understand and give written .
  2. Hepatocellular carcinoma, diagnosed by clinical or pathological diagnosis.
  3. Patients with advanced HCC, defined as those with macrovascular invasion, extrahepatic spread, or who failed or are not feasible to locoregional therapy.
  4. (ECOG) performance status ≤ 2.
  5. score A-B7.
  6. Sorafenib is deemed as an appropriate treatment option for the patient at the discretion of the investigator.
  7. Male subjects and female subjects of who engage in heterosexual intercourse must agree to use protocol-specified method(s) of as described in Appendices.
  8. Willing and able to comply with the requirements and restrictions in this protocol.

Exclusion criteria

Exclusion Criteria:

  1. Exposure to multikinase inhibitors or capecitabine within 1 week before starting the study treatment.
  2. Unresolved HFS.
  3. Exposure to oral NSAID, topical NSAID, or topical within 1 week before starting the study treatment.
  4. Known allergy to NSAID.
  5. Any concurrent systemic chemotherapy, immunotherapy, or biologic for cancer treatment.
  6. Recent gastrointestinal bleeding within 12 weeks.
  7. Female patients who are pregnant, breast-feeding, or male or female patients of who are not employing an effective method of .
  8. Have other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
  9. Any medical condition that, in the investigator's or sponsor's opinion, poses an undue risk to the patient's participation in the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    Experimental

    Prophylactic topical indomethacin

    Drug: Topical Indomethacin

Interventions

  • DrugIndomethacinStudies of IndomethacinIndomethacin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The participant will be provided with 2 tubes (20 gm each) per week in the first 4 weeks (D1, 8, 15, 22), 4 tubes per 2 weeks at the second 4 weeks (D29, 43), and 4 tubes per 4 weeks for the third 4 weeks (D57) suffice for topical application over 12 weeks. The participant will apply 1 g (1 g = two fingertip units \[FTU\]: one FTU for one surface of one hand) of 1% topical indomethacin on the palmar and dorsal surface of each hand twice daily (= 4g/day) until discontinuation of sorafenib or 12 weeks or development of HFS, whichever is earlier. If the patient has adequate residual indomethacin gel at the visit, the prescribing amount may be reduced accordingly.

06

What researchers measure

Primary outcomes

  1. All-grade hand-foot skin reaction rate during the first 12 weeks of sorafenib treatment

    The proportion of participants who experience any grade of hand-foot skin reaction during the first 12 weeks of sorafenib treatment. Hand-foot skin reaction severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. The grading scale ranges from Grade 1 to Grade 5, with higher grades indicating greater severity. For participants who discontinue sorafenib before Week 12, hand-foot skin reaction events will be assessed during the actual sorafenib treatment period.

    Time frame: From initiation of sorafenib treatment through Week 12, assessed up to 12 weeks.

Secondary outcomes

  1. Grade ≥2 hand-foot skin reaction rate during the first 12 weeks

    The proportion of participants who experience Grade 2 or higher hand-foot skin reaction during the first 12 weeks of sorafenib treatment. Hand-foot skin reaction severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. The grading scale ranges from Grade 1 to Grade 5, with higher grades indicating greater severity.

    Time frame: From initiation of sorafenib treatment through Week 12, assessed up to 12 weeks.

  2. Grade ≥3 hand-foot skin reaction rate during the first 12 weeks

    The proportion of participants who experience Grade 3 or higher hand-foot skin reaction during the first 12 weeks of sorafenib treatment. Hand-foot skin reaction severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. The grading scale ranges from Grade 1 to Grade 5, with higher grades indicating greater severity.

    Time frame: From initiation of sorafenib treatment through Week 12, assessed up to 12 weeks.

  3. Mean sorafenib dose intensity during the first 12 weeks of treatment

    Time frame: From initiation of sorafenib treatment through Week 12, assessed up to 12 weeks.

  4. Adverse events of special interest in the first 12 weeks of sorafenib treatment

    Time frame: From initiation of sorafenib treatment through Week 12, assessed up to 12 weeks.

  5. Treatment duration of sorafenib

    Time frame: From initiation of sorafenib treatment until permanent discontinuation of sorafenib, assessed up to 24 weeks.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Apr 2029, 40 months after the start.

Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 40 months is below that.

Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
May 1, 2026
StartActual
Dec 9, 2025
Primary completionEst.
Apr 30, 2029
CompletionEst.
Apr 30, 2029
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07560566
Responsible party
Sponsor
First posted
May 1, 2026
Start date
Dec 9, 2025
Primary completion
Apr 30, 2029 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
May 1, 2026

Study contacts

Yu-Yun Shao, M.D., Ph.D.
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Indomethacin

Start the discussion